A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Status:
Completed
Trial end date:
2020-06-12
Target enrollment:
Participant gender:
Summary
A Phase 3 (extension) clinical trial to examine the efficacy of IPI-145 monotherapy or
ofatumumab monotherapy in subjects with Chronic Lymphocytic Leukemia (CLL) or Small
Lymphocytic Lymphoma (SLL) who experienced disease progression after treatment with IPI-145
or Ofatumumab in Study IPI-145-07.